Pulmonary hypertension owing to left heart disease

Clinics in Chest Medicine

Volumn 34, Issue 4, 2013, Pages 683-694

  Mathier, Michael A ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Cardiac catheterization; Echocardiography; Heart failure; Hemodynamics; Pulmonary hypertension

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; SILDENAFIL;

DATA ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART CATHETERIZATION; HEART DISEASE; HEART OUTPUT; HISTORY OF MEDICINE; HUMAN; IMAGE ANALYSIS; LUNG FUNCTION TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROVOCATIVE MANEUVER; PULMONARY HYPERTENSION; REVIEW; THORAX RADIOGRAPHY; WAVEFORM;

CARDIAC CATHETERIZATION; ECHOCARDIOGRAPHY; HEART FAILURE; HEMODYNAMICS; PULMONARY HYPERTENSION;

CARDIAC CATHETERIZATION; DIAGNOSIS, DIFFERENTIAL; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; MAGNETIC RESONANCE IMAGING;

EID: 84888205867     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.09.004     Document Type: Review

References (46)

1. Voelkel N.F., Quaife R.A., Leinwand L.A., et al. Right ventricular function and failure: report of a National Heart, Lung, and Blood Institute working group on cellular and molecular mechanisms of right heart failure. Circulation 2006, 114:1883-1891.
2. Teuteberg J.J., Mathier M.A., Shullo M.A. Cardiac transplantation and circulatory support devices. Cardiovascular therapeutics 2013, 307-321. Elsevier, Philadelphia. E.M. Antman, M.S. Sabatine (Eds.).
3. Lam C.S., Roger V.L., Rodeheffer R.J., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. JAm Coll Cardiol 2009, 53:1119-1126.
4. Lam C.S., Borlaug B.A., Kane G.C., et al. Age-associated increases in pulmonary artery systolic pressure in the general population. Circulation 2009, 119:2663-2670.
5. Malouf J.F., Enriquez-Sarano M., Pellikka P.A., et al. Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications. JAm Coll Cardiol 2002, 40:789-795.
6. Vincens J.J., Temizer D., Post J.R., et al. Long-term outcome of cardiac surgery in patients with mitral stenosis and severe pulmonary hypertension. Circulation 1995, 92:II137-II142.
7. Umesan C.V., Kapoor A., Sinha N., et al. Effect of Inoue balloon mitral valvotomy on severe pulmonary arterial hypertension in 315 patients with rheumatic mitral stenosis: immediate and long-term results. JHeart Valve Dis 2000, 9:609-615.
8. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension. JAm Coll Cardiol 2009, 53:1573-1619.
9. Trow T.K., McArdle J.R. Diagnosis of pulmonary arterial hypertension. Clin Chest Med 2007, 28:59-73.
10. Nagaya N., Nishikimi T., Uematsu M., et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000, 102:865-870.
11. Silver M.A., Maisel A., Yancy C.W., et al. BNP Consensus Panel 2004: a clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail 2004, 10:1-30.
12. Alegro S., Morrison D., Ovitt T., et al. Noninvasive detection of pulmonary hypertension. Clin Cardiol 1984, 7:148-156.
13. Nasis A., Mottram P.M., Cameron J.D., et al. Current and evolving clinical applications of multidetector cardiac CT in assessment of structural heart disease. Radiology 2013, 267:11-25.
14. Jing Z.C., Xu X.Q., Badesch D.B., et al. Pulmonary function testing in patients with pulmonary arterial hypertension. Respir Med 2009, 103:1136-1142.
15. Bossone E., D'Andrea A., D'Alto M., et al. Echocardiography in pulmonary arterial hypertension: from diagnosis to prognosis. JAm Soc Echocardiogr 2013, 26:1-14.
16. Forfia P.R., Vachiéry J.L. Echocardiography in pulmonary arterial hypertension. Am J Cardiol 2012, 110(Suppl 6):16S-24S.
17. Opotowsky A.R., Ojeda J., Rogers F., et al. Asimple echocardiographic prediction rule for hemodynamics in pulmonary hypertension. Circ Cardiovasc Imaging 2012, 5:765-775.
18. Badesch D.B., Raskob G.E., Elliott C.G., et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010, 137:376-387.
19. Forfia P.R., Fisher M.R., Mathai S.C., et al. Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med 2006, 174:1034-1041.
20. Khouri S.J., Maly G.T., Suh D.D., et al. Apractical approach to the echocardiographic evaluation of diastolic function. JAm Soc Echocardiogr 2004, 17:290-297.
21. Owan T.E., Redfield M.M. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis 2005, 47:320-332.
22. Benza R., Biederman R., Murali S., et al. Role of cardiac magnetic resonance imaging in the management of patients with pulmonary arterial hypertension. JAm Coll Cardiol 2008, 52:1683-1692.
23. Roeleveld R.J., Marcus J.T., Boonstra A., et al. Acomparison of noninvasive MRI-based methods of estimating pulmonary artery pressure in pulmonary hypertension. JMagn Reson Imaging 2005, 22:67-72.
24. van Wolferen S.A., Marcus J.T., Boonstra A., et al. Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J 2007, 28:1250-1257.
25. van de Veerdonk M.C., Kind T., Marcus J.T., et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy. JAm Coll Cardiol 2011, 58:2511-2519.
26. Kuehne T., Yilmaz S., Steendijk P., et al. Magnetic resonance imaging analysis of right ventricular pressure-volume loops: invivo validation and clinical application in patients with pulmonary hypertension. Circulation 2004, 110:2010-2016.
27. Clinical cardiac MRI 2005, Springer-Verlag, Berlin Heidelberg. J. Bogaert, S. Dymarkowski, A.M. Taylor (Eds.).
28. Fang J.C., DeMarco T., Givertz M.M., et al. World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult-a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. JHeart Lung Transplant 2012, 31:913-933.
29. Grossman's cardiac catheterization, angiography, and intervention 2005, Lippincott Williams & Wilkins, Philadelphia. 7th edition. D.S. Baim (Ed.).
30. Hoeper M.M., Lee S.H., Voswinckel R. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. JAm Coll Cardiol 2006, 48:2546-2552.
31. Hoeper M.M., Maier R., Tongers J. Determination of cardiac output by the Fick method, thermodilution, and acetylene rebreathing in pulmonary hypertension. Am J Respir Crit Care Med 1999, 160:535-541.
32. Fares W.H., Blanchard S.K., Stouffer G.A., et al. Thermodilution and Fick cardiac outputs differ: impact on pulmonary hypertension evaluation. Can Respir J 2012, 19:261-266.
33. Givertz M.M., Hare J.M., Loh E., et al. Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. JAm Coll Cardiol 1996, 28:1775-1780.
34. Kovacs G., Berghold A., Scheidl S., et al. Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009, 34:888-894.
35. Naeije R., Vanderpool R., Dhakal B.P., et al. Exercise-induced pulmonary hypertension: physiological basis and methodological concerns. Am J Respir Crit Care Med 2013, 187:576-583.
36. Halpern S.D., Taichman D.B. Misclassification of pulmonary hypertension due to reliance on pulmonary capillary wedge pressure rather than left ventricular end-diastolic pressure. Chest 2009, 136:37-43.
37. Ryan J.J., Rich J.D., Thiruvoipati T., et al. Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J 2012, 163:589-594.
38. Hunt S.A., Abraham W.T., Chin M.H., et al. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in Adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the International Society for heart and lung transplantation. JAm Coll Cardiol 2009, 53:e1-e90.
39. Mikus E., Stepanenko A., Krabatsch T., et al. Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg 2011, 40:971-977.
40. Zakliczynski M., Maruszewski M., Pyka L., et al. Effectiveness and safety of treatment with sildenafil for secondary pulmonary hypertension in heart transplant candidates. Transplant Proc 2007, 39(9):2856-2858.
41. Perez-Villa F., Farrero M., Cardona M., et al. Bosentan in heart transplantation candidates with severe pulmonary hypertension: efficacy, safety and outcome after transplantation. Clin Transplant 2013, 27:25-31.
42. Califf R.M., Adams K.F., McKenna W.J., et al. Arandomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997, 134:44-54.
43. Teerlink J.R. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy?. JCard Fail 2002, 8:124-127.
44. Lewis G.D., Shah R., Shahzad K., et al. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation 2007, 116:1555-1562.
45. Guazzi M., Vicenzi M., Arena R., et al. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 2011, 124:164-174.
46. Redfield M.M., Chen H.H., Borlaug B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013, 309:1268-1277.